Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical screen not yet scored
Price7.97 USD
Fair value21.80
Ethical score70.0/100
Our investment reviews on this name
2026-10-02Read Markdown10.90-26.9% to today ✓Accumulation gives way to Markdown first Markdown read since July
2026-09-05Read Accumulation11.38-30.0% to today Distribution gives way to Accumulation after a 70% slide in 4 weeks
2026-08-05Read Distribution37.87-79.0% to today ✓Markdown gives way to Distribution after a 36% rise in 5 weeks
2026-07-02Read Markdown27.75-71.3% to today ✓First review on file: Markdown
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
MapLight Therapeutics, Inc. holds its Markdown at $7.97. The statistical read favours the sellers, held for 40 days.
As held on the ledger · 2026-10-23
Phase
Markdown · caution
Quantitative state
The statistical read favours the sellers, held for 40 days
Price at the screen
$7.97
Valuation
N/A trailing · -3.17 forward price to earnings
Values screen
Not scored· score 70.0
The Workings
Five Screens, Shown in Full
This security has not been fully scored against the values screen yet.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
1.21%
Below 33%
Interest-bearing debt is just 1.2% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
30.86%
Below 33%
Cash held in interest-bearing accounts and securities is 30.9% of assets, under the one-third limit.
Pass
Receivables
9.75%
Below 49%
Money owed to the company is 9.7% of assets, under the 49% limit.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
The Read, in Plain English
MapLight Therapeutics, clears the business-activity screen and the figures we can measure look clean, but its income-purity figure is still pending, so the verdict is not final yet.
Read as at 2026-10-28. It updates when the underlying figures move, and past reads are kept below.
Fair value range in USD, drawn from the 2026-10-23 screen. The gold marker is the market price at the same screen. A 100.0% margin of safety to the base estimate.
Third-party analyst targets: 13 covering, consensus Strong Buy. The average target sits +276% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-23 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Clinical Biotech With No Profit Track Record
Picture a lab racing to fix serious brain disorders while burning cash every quarter with nothing yet on the market. MapLight sits in that exact spot, a clinical stage name with zero profit margin, an ROE of minus 81 percent and a forward multiple that simply reflects ongoing losses. We pass because the ethical screen has no financial ratio data at all, leaving us unable to judge the business on any normal standard.
Analysts still see upside to around 42 dollars from the current 37.87, yet the opportunity rating sits at none. A pre revenue biotech with an unknown moat offers little to anchor on beyond hope in one pipeline asset. The margin of safety looks thin once you strip away the consensus noise.
Risks run from trial failure and dilution to the simple fact that we cannot clear the basic ethical hurdles here. Currency and sector swings would only add to the uncertainty. Analysis, not advice.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
MPLT trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-28Markdown$7.88+0.0%Entry 9
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading bearish. Our forward projection puts the odds of a 10% gain over the next month near 44%. The street (10 analysts) rates it strong buy, with a mean price target of $38. Insiders have been net sellers over the past quarter.
2026-10-21Markdown$7.88-10.8%Entry 8
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 10.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading oversold. Our forward projection puts the odds of a 10% gain over the next month near 44%. The street (10 analysts) rates it strong buy, with a mean price target of $38. Insiders have been net sellers over the past quarter.
2026-10-14Markdown$8.83-19.0%Entry 7
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 19.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. Our forward projection puts the odds of a 10% gain over the next month near 44%. The street (10 analysts) rates it strong buy, with a mean price target of $38.
2026-10-02Markdown · changed$10.90-4.2%Entry 6
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 4.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading neutral. Our forward projection puts the odds of a 10% gain over the next month near 44%. The street (10 analysts) rates it strong buy, with a mean price target of $38.
The framework has shifted from distribution to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 69.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading neutral. Our forward projection puts the odds of a 10% gain over the next month near 44%. The street (10 analysts) rates it strong buy, with a mean price target of $38.
The framework has shifted from markdown to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 36.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading neutral. Our forward projection puts the odds of a 10% gain over the next month near 44%. The street (10 analysts) rates it strong buy, with a mean price target of $38.
2026-07-18Markdown$27.75+0.0%Entry 3
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading neutral. Our forward projection puts the odds of a 10% gain over the next month near 44%. The street (10 analysts) rates it strong buy, with a mean price target of $38.
2026-07-03Markdown$27.75+0.0%Entry 2
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns.
2026-07-02Markdown$27.75Entry 1
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.